EP2751129A4 - Protein p14 mit krebshemmender sowie antiallergischer wirkung und pharmazeutische zusammensetzung damit - Google Patents

Protein p14 mit krebshemmender sowie antiallergischer wirkung und pharmazeutische zusammensetzung damit

Info

Publication number
EP2751129A4
EP2751129A4 EP12851727.3A EP12851727A EP2751129A4 EP 2751129 A4 EP2751129 A4 EP 2751129A4 EP 12851727 A EP12851727 A EP 12851727A EP 2751129 A4 EP2751129 A4 EP 2751129A4
Authority
EP
European Patent Office
Prior art keywords
cancer
protein
pharmaceutical composition
same
allergy activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12851727.3A
Other languages
English (en)
French (fr)
Other versions
EP2751129B1 (de
EP2751129A1 (de
Inventor
Jae Gu Seo
Myung Jun Chung
Hyun Gi Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Biotech Co Ltd
Original Assignee
Cell Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110123033A external-priority patent/KR101427363B1/ko
Priority claimed from KR1020110123030A external-priority patent/KR101377617B1/ko
Application filed by Cell Biotech Co Ltd filed Critical Cell Biotech Co Ltd
Publication of EP2751129A1 publication Critical patent/EP2751129A1/de
Publication of EP2751129A4 publication Critical patent/EP2751129A4/de
Application granted granted Critical
Publication of EP2751129B1 publication Critical patent/EP2751129B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP12851727.3A 2011-11-23 2012-08-29 Protein p14 mit krebshemmender sowie antiallergischer wirkung und pharmazeutische zusammensetzung damit Active EP2751129B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020110123033A KR101427363B1 (ko) 2011-11-23 2011-11-23 항암 약제학적 조성물
KR1020110123030A KR101377617B1 (ko) 2011-11-23 2011-11-23 항알러지 활성을 갖는 피14 단백질 및 이들을 포함하는 항알러지 약제학적 조성물
PCT/KR2012/006906 WO2013077534A1 (en) 2011-11-23 2012-08-29 Protein p14 with anti-cancer and anti-allergy activity and pharmaceutical composition comprising the same

Publications (3)

Publication Number Publication Date
EP2751129A1 EP2751129A1 (de) 2014-07-09
EP2751129A4 true EP2751129A4 (de) 2015-04-01
EP2751129B1 EP2751129B1 (de) 2018-01-24

Family

ID=48469946

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12851727.3A Active EP2751129B1 (de) 2011-11-23 2012-08-29 Protein p14 mit krebshemmender sowie antiallergischer wirkung und pharmazeutische zusammensetzung damit

Country Status (3)

Country Link
EP (1) EP2751129B1 (de)
DK (1) DK2751129T3 (de)
WO (1) WO2013077534A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101910808B1 (ko) * 2016-11-28 2018-10-24 주식회사 쎌바이오텍 유산균 유래 p8 단백질 및 이의 항암 용도
KR20180087662A (ko) * 2017-01-25 2018-08-02 주식회사 쎌바이오텍 유산균 유래 단백질 및 시스타틴을 포함하는 대장질환 치료용 약학조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008113A1 (en) * 2008-07-17 2010-01-21 Cell Biotech Co., Ltd. Anti-cancer composition comprising a culture fluid of lactobacillus casei as an effective component

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
JPH05503003A (ja) 1989-11-22 1993-05-27 ジェネンテク，インコーポレイテッド 潜在性関与ペプチドおよびその使用
KR101016708B1 (ko) * 2008-05-08 2011-02-25 주식회사 유니젠 항알러지 효과가 있는 ＰｒｏＡＬ 단백질을 암호화하는유전자

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008113A1 (en) * 2008-07-17 2010-01-21 Cell Biotech Co., Ltd. Anti-cancer composition comprising a culture fluid of lactobacillus casei as an effective component

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 16 June 2009 (2009-06-16), "SubName: Full=Uncharacterized protein {ECO:0000313|EMBL:EEI67472.1}; QVF", XP002735999, retrieved from EBI accession no. UNIPROT:C2FF76 Database accession no. C2FF76 *
DATABASE UniProt [online] 16 June 2009 (2009-06-16), "SubName: Full=Uncharacterized protein {ECO:0000313|EMBL:EEN80201.1}; QVF", XP002736000, retrieved from EBI accession no. UNIPROT:C2JXM4 Database accession no. C2JXM4 *
K. MAKAROVA ET AL: "Comparative genomics of the lactic acid bacteria", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 103, no. 42, 17 October 2006 (2006-10-17), pages 15611 - 15616, XP055004004, ISSN: 0027-8424, DOI: 10.1073/pnas.0607117103 *
See also references of WO2013077534A1 *

Also Published As

Publication number Publication date
DK2751129T3 (en) 2018-02-05
WO2013077534A1 (en) 2013-05-30
EP2751129B1 (de) 2018-01-24
EP2751129A1 (de) 2014-07-09

Similar Documents

Publication Publication Date Title
IL286784A (en) Compositions of protein and antibody
EP2905290A4 (de) Heterodimere proteinzusammensetzung
IL279676A (en) Recombinant proteins and therapeutic uses
HRP20181210T1 (hr) Fuzijski protein koji sadrži interleukin 4 i interleukin 10
SG10201601327RA (en) Glycosylated polypeptide and drug composition containing said polypeptide
PT2858490T (pt) Elementos de adn recombinantes para a expressão de proteínas recombinantes em insetos
EP2718283A4 (de) Indazol- und pyrrolopyridin-derivat sowie pharmazeutische verwendung davon
EP2711376A4 (de) Fgfr-fc-fusionsprotein und verwendung davon
EP2930189A4 (de) Chemokin-cytokin-fusionsprotein und anwendung davon
HK1204948A1 (en) Radiation-sterilization-resistant protein composition
SG10201601324VA (en) Glycosylated polypeptide and drug composition containing said polypeptide
EP2930183A4 (de) Rekombinantes protein und verwendungen zur diagnose von multipler sklerose
EP2751129A4 (de) Protein p14 mit krebshemmender sowie antiallergischer wirkung und pharmazeutische zusammensetzung damit
SG10201602076QA (en) Glycosylated polypeptide and pharmaceutical composition containing same
IL232809A (en) Carboxamides are preserved in position 2 isothiazolopyridine-2-carboxamides and used as drugs
HK1211952A1 (en) Recombinant protein
GB201112578D0 (en) Pharmaceutical preparation and use
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140307

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150303

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/74 20150101ALI20150220BHEP

Ipc: A61P 37/08 20060101ALI20150220BHEP

Ipc: A61K 38/16 20060101ALI20150220BHEP

Ipc: A61P 35/00 20060101ALI20150220BHEP

Ipc: C07K 14/335 20060101AFI20150220BHEP

17Q First examination report despatched

Effective date: 20161121

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170807

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180131

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 965700

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012042481

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180124

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 965700

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180424

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180424

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180524

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012042481

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20181025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180829

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180124

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180124

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180829

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230818

Year of fee payment: 12

Ref country code: GB

Payment date: 20230818

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230815

Year of fee payment: 12

Ref country code: DK

Payment date: 20230818

Year of fee payment: 12

Ref country code: DE

Payment date: 20230821

Year of fee payment: 12